Formamide

Formamide

SCHEMBL446005

COc1cnccn1.NC=O

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.49
KDM4E B2RXH2 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.41
SIRT6 Q8N6T7 1/20 0.39
KMT2A Q03164 2/20 0.37
HSP90AA1 P07900 1/20 0.37
PLAU P00749 1/20 0.36
ADORA3 P0DMS8 1/20 0.35
TSHR P16473 1/20 0.35
MC4R P32245 1/20 0.35
ADRA1A P35348 1/20 0.35
MC3R P41968 1/20 0.35
LOX P28300 1/20 0.35
LOXL2 Q9Y4K0 1/20 0.35
AURKA O14965 1/20 0.35
TTK P33981 1/20 0.35
AURKB Q96GD4 1/20 0.35
INCENP Q9NQS7 1/20 0.35
NNMT P40261 1/20 0.34
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29445963 0.87
SCHEMBL13359011 0.87 MAPT (0.45) MAPTKDM4ESMN1; SMN2SIRT6KMT2A
SCHEMBL391812 0.87
Formaldehyde SCHEMBL27596059 0.85 MAPT (0.45) MAPTKDM4ESMN1; SMN2SIRT6KMT2A
Ammonia Solution, Strong SCHEMBL28148961 0.85
Ethane SCHEMBL5007888 0.85 MAPT (0.44) MAPTKDM4ESMN1; SMN2SIRT6KMT2A
Ammonia Solution, Strong SCHEMBL27633176 0.83 MAPT (0.42) MAPTKDM4ESMN1; SMN2SIRT6KMT2A
Butadiene SCHEMBL896495 0.82 MAPT (0.43) MAPTKDM4ESMN1; SMN2SIRT6KMT2A
Isobutane SCHEMBL996078 0.81 MAPT (0.41) MAPTKDM4ESMN1; SMN2SIRT6KMT2A
Ethoxycarbonyl Group SCHEMBL28310600 0.80 MAPT (0.43) MAPTKDM4ESMN1; SMN2SIRT6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-03-15 US claimed
WO-2011123674-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2011-10-06 WO claimed
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-03-15 US disclosed
WO-2011123674-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2011-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES APP, BACE1, PSEN1 MAPT 14/4885KDM4E 4178/4885SMN1; SMN2 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.